Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ADC THERAPEUTICS SA

(ADCT)
  Report
Delayed Nyse  -  04:00 2022-12-02 pm EST
3.620 USD   +4.02%
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/28ADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targets
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about ADC THERAPEUTICS SA
11/28Biocytogen Enters into Antibody Agreement with ADC Therapeutics
BU
11/28ADC Therapeutics, Biocytogen Pharmaceuticals Sign Antibody License Deal for Tumor Targe..
MT
11/14Sobi to present new data at the ASH 2022 Annual Meeting
AQ
11/14Morgan Stanley Adjusts Price Target on ADC Therapeutics SA to $7 From $11, Maintains Eq..
MT
11/09BofA Securities Downgrades ADC Therapeutics to Neutral From Buy, Adjusts Price Target t..
MT
11/09RBC Cuts Price Target on ADC Therapeutics to $20 From $25, Notes Delay in Potential Cam..
MT
11/08Transcript : ADC Therapeutics SA, Q3 2022 Earnings Call, Nov 08, 2022
CI
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 Revenue $76.3M
MT
11/08Earnings Flash (ADCT) ADC THERAPEUTICS SA Posts Q3 EPS $0.13
MT
11/08Adc Therapeutics : Purchase Agreement - Form 6-K
PU
11/08ADC Therapeutics SA Reports Earnings Results for the Third Quarter and Nine Months Ende..
CI
11/08ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Upd..
BU
11/07ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
BU
11/03ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual M..
BU
11/02IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evalu..
BU
11/02IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evalu..
AQ
11/02IGM Biosciences, Inc. Enters into Clinical Trial Collaboration and Supply Agreement wit..
CI
11/01ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Pete..
BU
11/01ADC Therapeutics SA Announces Executive Changes
CI
10/31ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Novemb..
BU
10/06RBC Cuts Price Target on ADC Therapeutics to $25 From $29, Maintains Outperform Rating
MT
09/22ADC Therapeutics SA Announces Abstracts to Be Presented at the Tenth Annual Meeting of ..
CI
09/21ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the..
BU
09/21JPMorgan Starts ADC Therapeutics at Underweight with $5 Price Target
MT
09/19HC Wainwright Adjusts ADC Therapeutics' Price Target to $21 From $20, Maintains Buy Rat..
MT
09/16ADC Therapeutics, Sobi Say CHMP Opinion Positive for Zynlonta for Relapsed or Refractor..
MT
09/16Swedish Orphan Biovitrum, ADC Therapeutics Win Recommendation For Lymphoma Medication
MT
09/16ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive..
CI
09/16ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive..
BU
09/16ADC Therapeutics, Swedish Orphan Biovitrum's Co-Developed Drug Recommended for EU Autho..
DJ
09/13Transcript : ADC Therapeutics SA Presents at Morgan Stanley 20th Annual Globa..
CI
09/09Morgan Stanley Downgrades ADC Therapeutics to Equalweight From Overweight, Cuts Price T..
MT
09/07ADC Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare Confe..
AQ
09/06ADC Therapeutics to Participate in Morgan Stanley's 20th Annual Global Healthcare Confe..
BU
08/22HC Wainwright Adjusts Price Target on ADC Therapeutics SA to $20 From $44, Reiterates B..
MT
08/15Adc Therapeutics : WARRANT TO PURCHASE COMMON SHARES OF ADC THERAPEUTICS SA - Form 6-K
PU
08/15ADC Therapeutics Lands $175 Million Term Loan, Settles Convertible Notes; Shares Rise A..
MT
08/15ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oakt..
BU
08/15ADC Therapeutics SA announced that it expects to receive $181.249999 million in funding..
CI
08/09Adc Therapeutics : Purchase Agreement - Form 6-K
PU
08/09Transcript : ADC Therapeutics SA, Q2 2022 Earnings Call, Aug 09, 2022
CI
08/09ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Up..
BU
08/09ADC Therapeutics SA Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
08/02Adc Therapeutics : to Host Second Quarter 2022 - Form 6-K
PU
08/02ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on Augus..
BU
07/27ADC Therapeutics Doses First Patient in Early Trial of ADCT-601 to Treat Solid Tumors
MT
07/27Adc Therapeutics : Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AX..
PU
07/27ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting A..
BU
07/27ADC Therapeutics SA Doses First Patient in Phase 1B Clinical Trial of ADCT-601
CI
07/20ADC Therapeutics Doses First Patient in Phase 2 Clinical Trial of Zynlonta, Rituximab C..
MT
07/20Adc Therapeutics : Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (l..
PU
07/20ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (..
BU
07/20ADC Therapeutics SA Announces First Patient Dosed in Phase 2 Clinical Trial of Zynlonta..
CI
07/11ADC Therapeutics SA Enters into License Agreement with Swedish Orphan Biovitrum AG
CI
07/11ADC Therapeutics' Joint Venture Doses First Patient in Phase 3 Trial of Lymphoma Drug C..
MT
07/11Adc Therapeutics : Overland ADCT BioPharma Announces First Patient Dosed in China with ZYN..
PU
07/11Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combin..
BU
07/11Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combin..
CI
07/11HC Wainwright Adjusts Price Target on ADC Therapeutics to $44 From $54, Reiterates Buy ..
MT
07/08Sector Update: Health Care Stocks Add to Earlier Friday Advance
MT
07/08Sector Update: Health Care Stocks Rise in Defensive Session
MT
07/08Sector Update: Health Care
MT
07/08Sector Update: Health Care Stocks Mixed Pre-Bell Friday
MT
07/08ADC Therapeutics, Sobi Enter Into License Agreement for Loncastuximab Tesirine in Europ..
MT
07/08Sobi Secures Exclusive Rights to ADC Therapeutics' Blood Cancer Drug
MT
07/08Sobi to license loncastuximab tesirine from ADC Therapeutics
AQ
07/08ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commerc..
BU
07/08ADC Therapeutics Announces Exclusive License Agreement with Swedish Orphan Biovitrum AB..
CI
07/01ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
BU
06/30ADC Therapeutics SA Elects Jean-Pierre Bizzari and Ameet Mallik as Members of the Board..
CI
06/29ADC Therapeutics Doses First Patient in Trial of Cancer Drug Candidate
MT
06/29ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastux..
BU
06/29ADC Therapeutics SA Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncas..
CI
06/13Adc Therapeutics : Names David Gilman as Chief Business & Strategy Officer - Form 6-K
PU
06/13ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
BU
1  2  3  4  5  6Next